This global Enzyme Replacement Therapy Market report is generated based on the market type, size of the organization, availability on-premises and the end-users’ organization type. The current market scenario and future prospects of the sector have also been examined in the most excellent Enzyme Replacement Therapy Market report. It is a professional and detailed report that highlights primary and secondary drivers, market share, leading segments and geographical analysis. The report also analysis the emerging trends along with major drivers, challenges and opportunities in the Enzyme Replacement Therapy Market .
The global enzyme replacement therapy market size was USD 10.56 billion in 2020. The market is projected to grow from USD 11.43 billion in 2021 to USD 20.58 billion in 2028 at a CAGR of 8.8% during the 2021-2028 period.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions.Due to high demand and the value of market research for the success of different sectors, Enzyme Replacement Therapy Market report has been prepared by covering many work areas.
Key players covered in the global Enzyme Replacement Therapy Market research report:
- BioMarin (San Rafael, U.S.)
- Leadiant Biosciences, Inc. (Gaithersburg, U.S.)
- Pfizer Inc. (New York, U.S.)
- Sanofi (Paris, France)
- AbbVie Inc. (Lake Bluff, U.S.)
- Takeda Pharmaceutical Company Limited (Tokyo, Japan)
- JCR Pharmaceutical Co., Ltd. (Ashiya, Japan)
- Nestlé (Vevey, Switzerland)
Drivers & Restraints
There is a gradual increase in the global prevalence of different lysosomal storage disorders such as Gaucher, Fabry, Pompe, and MPS. For instance, according to the data published by the National Institute of Neurological Disorders and Stroke in August 2021, around 1 in 40,000 people in the U.S. were suffering from Pompe disease,which is estimated to be around 32,950. Also, according to the National Fabry foundation, in May 2020, the total Fabry patient population in the U.S. was around 7,713. Thus, the presence of a large patient pool suffering from rare lysosomal storage disorders generates higher demand for effective treatment options such as enzyme replacement therapy.